Trial · NCT02199743

Lurasidone Effects on Tissue Glutamate in Schizophrenia

NCT02199743, Phase 4, Completed, University of Texas Southwestern Medical Center; results first posted 2021-03-01

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Lurasidone Effects on Tissue Glutamate in Schizophrenia. Trials, record NCT02199743. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02199743

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Lurasidone Effects on Tissue Glutamate in Schizophrenia
NCT number: NCT02199743
Status: Completed
Phases: Phase 4
Enrollment: 35 participants, actual
Lead sponsor: University of Texas Southwestern Medical Center
Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Lurasidone, Haloperidol, Perphenazine
First posted: 2014-07-24
Last updated: 2021-03-01
Results first posted: 2021-03-01

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Cerebral Glutamate Levels	Baseline and 4 weeks	Mean values of cerebral glutamate levels was measured by high resolution 3T magnetic resonance spectroscopy (MRS) in the anterior cingulate cortex (ACC). Data were acquired from the dorsal anterior cingulate cortex (ACC) using single voxel localized PRESS (TE1, TE2) = (32, 65) ms with an 8-channel head coil in a 3T whole-body scanner (Philips Medical Systems). Voxel size was 30x20x15 mm3 (9 mL) and were placed over the bilateral anterior cingulate cortex (ACC). All values are normalized to water. More negative values represent less cerebral glutamate levels.
Secondary	Brief Assessments of Cognition in Schizophrenia Scores (BACS)	Baseline and 4 weeks	Mean of cognition was assessed by BACS, which measures neurocognitive function in schizophrenia. BACs is a validated, composite measure of cognition which is used in schizophrenia. It is composed of Verbal memory (range: 0-75), Working memory (range: 0-28), Motor speed (range: 0-100), Verbal Fluency (number of words generated), Information processing (range: 0-110) and Executive functions (range: 0-22). Higher z-scores indicate a better performance and outcome. BACS composite score are represented as z-scores which can be positive or negative. There is no minimum or maximum as this is a continuous measure.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Cerebral Glutamate Levels	Baseline and 4 weeks	Of the original 22 participants, only 15 have both Baseline and Week 4 scans to compare.	relative unit (RU as compared to water)	MEAN
SECONDARY	Brief Assessments of Cognition in Schizophrenia Scores (BACS)	Baseline and 4 weeks	Of the original 22 participants, only 15 have both Baseline and Week 4 to compare.	BACS composite score (z score)	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Cerebral Glutamate Levels	Lurasidone	Baseline (week 0)	-1.434662171	Standard Deviation 0.741430931	relative unit (RU as compared to water)
Cerebral Glutamate Levels	Non-Lurasidone	Baseline (week 0)	-1.933853656	Standard Deviation 1.005387144	relative unit (RU as compared to water)
Cerebral Glutamate Levels	Lurasidone	week 4	-1.412294235	Standard Deviation 0.952600355	relative unit (RU as compared to water)
Cerebral Glutamate Levels	Non-Lurasidone	week 4	-1.838991525	Standard Deviation 1.20411535	relative unit (RU as compared to water)
Brief Assessments of Cognition in Schizophrenia Scores (BACS)	Lurasidone	Baseline (week 0)	-1.596573107	Standard Deviation 0.929835487	BACS composite score (z score)
Brief Assessments of Cognition in Schizophrenia Scores (BACS)	Non-Lurasidone	Baseline (week 0)	-1.933853656	Standard Deviation 1.005387144	BACS composite score (z score)
Brief Assessments of Cognition in Schizophrenia Scores (BACS)	Lurasidone	week 4	-2.002433521	Standard Deviation 1.596431421	BACS composite score (z score)
Brief Assessments of Cognition in Schizophrenia Scores (BACS)	Non-Lurasidone	week 4	-1.500292967	Standard Deviation 1.477111055	BACS composite score (z score)

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Lurasidone	14
Overall Study	STARTED	Non-Lurasidone	10
Overall Study	COMPLETED	Lurasidone	14
Overall Study	COMPLETED	Non-Lurasidone	8
Overall Study	NOT COMPLETED	Lurasidone	0
Overall Study	NOT COMPLETED	Non-Lurasidone	2

Source ClinicalTrials.gov

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Sedation	Psychiatric disorders	Lurasidone (LUR)	3	14	3
other	Sedation	Psychiatric disorders	NONLUR	4	8	4
other	Nausea	Gastrointestinal disorders	Lurasidone (LUR)	0	14	0
other	Nausea	Gastrointestinal disorders	NONLUR	2	8	2
other	Insomnia	General disorders	Lurasidone (LUR)	3	14	3
other	Insomnia	General disorders	NONLUR	0	8	0
other	Restlessness	General disorders	Lurasidone (LUR)	0	14	0
other	Restlessness	General disorders	NONLUR	3	8	3
other	Stiffness in jaw	Musculoskeletal and connective tissue disorders	Lurasidone (LUR)	2	14	2
other	Stiffness in jaw	Musculoskeletal and connective tissue disorders	NONLUR	0	8	0

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Lurasidone (LUR)
Total, all-cause mortality	NONLUR
Total, other adverse events	Lurasidone (LUR)	3	14
Total, other adverse events	NONLUR	4	8
Total, serious adverse events	Lurasidone (LUR)	1	14
Total, serious adverse events	NONLUR	0	8

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
39831535	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Lurasidone (LUR) vs NONLUR: serious adverse events

Source Trial comparisons

Tests1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as
Verbal Fluency	Secondary outcome

Source ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02199743

GET https://conductscience.org/api/trials/v1/NCT02199743/registered

API reference For AI assistants